Madison Conces, MD

GI Medical Oncologist @UHhospitals Seidman Cancer Center @caseccc. Hematology/Oncology & IM trained via @ClevelandClinic. IUSM grad. Tweets are my own.

[Madison Conces, MD @MadisonConces]

@KRASKickers is an incredible patient advocate group and resource for our patients. 💪

Please take a moment to submit a message of support to patients with KRAS mutated tumors. Revolution Medicine will donate $50 for each message up to $30,000 to @KRASKickers ⬇️

[KRAS Kickers @KRASKickers]

This month, Revolution Medicines will donate $50 to @KRASKickers for every message of support submitted for up to $30,000.

Plant a seed of hope. Share your message:

LINK:
"Share a few words of encouragement for people impacted by RAS-addicted cancers. Your message will be collected as part of this shared expression of hope."

https://t.co/zq8qZfZvto

Thank you to @RevMedicines !

[Madison Conces, MD @MadisonConces]

@KRASKickers Done

[Scott Hadland, MD @DrScottHadland]

New JAMA study out today: In 5.2 million US babies: the % skipping vit K shot at birth more than doubled since 2017. And babies who skipped it had >2x the risk of a brain bleed.

Vitamin K is not a vaccine. It is a vitamin babies are in low in at birth. One shot saves lives.

[nature @Nature]

Scientists pay tribute to Marta Shahbazi Alonso and Tamara González Costa who died on their way to a developmental-biology meeting

https://t.co/cqpeHRiSMQ

[Madison Conces, MD @MadisonConces]

@kidney_boy Terrible. 💔💔💔

[Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD]

terrible for this girl but a sincere warning to our many pts using AI for med advice

[Dr. Anthony Letai @NCIDirector]

Hepatitis B and C, heavy alcohol use, and fatty liver disease all raise the risk of liver cancer, and some of those risks can be lowered. For #LiverCancerAwarenessMonth, @theNCI has plain-language information on risk and options: https://t.co/BTrCOQIisY

[Dr. Cathy Eng @CathyEngMD]

PRABITAS phase III trial pragmatic trial enrolled 972 pts in 17M evaluating the schedule of TAS-102 + bev (2 weeks on/2 weeks off) vs. (1 week on/1 week off) which validates non-inferiority and less dose reductions validating our RWD approach in the US. #colorectal #cancer #ESMO2026 @OncoAlert

[Dr. Cathy Eng @CathyEngMD]

Phase I encouraging results with INCB161734 (#KRAS #G12D) inhibitor 1200 mg + cetuximab (N=25) in #colorectal #cancer
- No grade 4/5 SAE's
- ORR = 36%
- DOR = 100%
- Median PFS = 7.2M
#ESMO2026 #RAS @Incyte @OncoAlert

[Arndt Vogel @ArndtVogel]

Biweekly vs conventional trifluridine/tipiracil plus bevacizumab for refractory mCRC: The pragmatic ph 3 PRABITAS trial
#ESMO26 #ESMOAmbassadors
👉ORR: 2 vs 2%
👉 mPFS: 3.9 vs 3.9 mo
👉 mOS: 10.3 vs 11.3 mo
🧐similar efficacy, less toxicity, supports biweekly schedule
@myESMO @ASCO

[Daisuke Kotani, MD, Ph.D @DaisukeKotani]

#ESMO26 | LBA31
PRABITAS: Pragmatic Ph3 biweekly FTD/TPI + bev vs conventional FTD/TPI + bev in mCRC (non-inferiority)
▪️OS: 11.3 vs 10.3 mo, HR 0.93, 95% CI 0.80-1.08 (<1.25)
▪️PFS: 3.9 vs 3.9 mo, HR 0.93, 95% CI 0.81-1.06
▪️Safety
- ≥G3 neutropenia: 13% vs 39%
- FN: 1% vs 5%
- ≥G2 anorexia: 15% vs 26%
👉Biweekly FTD/TPI + bev showed non-inferior OS with less toxicities!
@myESMO @OncoAlert

[Yakup Ergün @dr_yakupergun]

NICHE-2 | 5-year results

Just 2 doses of neoadjuvant nivo + 1 dose of ipi, followed by surgery...

Not a single recurrence after nearly 5 years of follow-up, and 5-year OS was 100%!

What more could we ask for?

I'm truly at a loss for words👏

https://t.co/dmnH26oA2L

[UH Research & Education Institute @UH_RE_Institute]

This #NationalDisabilityEmploymentAwarenessMonth, we're celebrating Elizabeth Bryson, a PhD candidate at @CWRUSOM whose IBD research is advancing potential new therapies while helping make science more accessible and inclusive. Read more: https://t.co/jDnVmAaTe1

[Madison Conces, MD @MadisonConces]

@UGrewalMD That’s very frustrating. Is there a way to reach out to the editor? I know at least some journals have made it clear to reviewers that using AI to review is not allowed. I think it’s reasonable to share your concerns.

[Anirban Maitra @Aiims1742]

“It’s been a journey” Shroff told @NBCNews. “I’ve spent my entire life trying to eradicate cancer, primarily pancreatic cancer, but also liver cancers.”
https://t.co/qGmDCVg30K
An homage to Rachna Shroff, including thoughts from her family. Please read, share &amp; honor her memory.

[Flavio G Rocha, MD, FACS, FSSO @FlavioRochaMD]

It has been a difficult week processing it all.
Rachna truly reflected the best of us &amp; her
legacy will live on in the patients she cared for,
the trainees she mentored, the colleagues she
brought together &amp; everyone she inspired

She always did what all stars do best…Shine

[Mark Lewis, MD, FASCO @marklewismd]

There is an especially outlandish conspiracy theory that oncologists are hiding the cure for cancer

Its proponents must think us particularly noble, then, when we sacrifice our lives to keep the secret: forgoing a panacea and succumbing to the very disease we treat

Dr. Shroff is not the only “wounded healer” I’ve known, but her legacy is far more than the wretched illness that claimed her own life too soon

She did her very best to push oncology forward, especially for patients with notoriously difficult-to-treat biliary tract cancers (a close relative, anatomically and sometimes pathophysiologically, to pancreatic adenocarcinoma)

I remember her incredible humility to stand at the podium at one of our largest scientific conferences and admit that a triplet therapy had not produced the benefits she had hoped for, allowing biological plausibility to cede to data yielded from the clinical trial she conceived & ran

Our field is full of such examples of good ideas failing to reach fruition, but we can only get better by admitting what’s not working as well as promoting true advances

When the history books are written, most, if not all chemo will look like grand folly, akin to our modern view of, say, blood-letting

But it is because of visionary physician-scientists like Rachna that we are making any progress at all: doing the best we can today while realizing there must be a better way and testing rigorously our ideas of how we might get there

May she be remembered in part for her tireless work, born out of irrepressible hope and true caring for her own patients as well as ones she never met (she never failed to kindly & helpfully answer a question I posed to her when I faced a management conundrum in her niche of cholangiocarcinoma)

RIP to a dear colleague (link in post below to a fund for young investigators named & bestowed in her honor)

[Cholangiocarcinoma Foundation @curecc]

It is with heavy hearts that we share that Dr. Rachna Shroff has passed away. A longtime partner of CCF, she has made tangible differences for patients and their families throughout her career. From being a valued member of our Science and Medical Advisory Board to helping build one of the nation's largest clinical and research programs in biliary tract cancer as a faculty member at MD Anderson Cancer Center, and as an empathetic and expert clinician, she made a difference in every facet.

Beyond her professional accomplishments, she brought fun everywhere she went. Whether she was quoting Beyoncé in a talk about clinical trials or getting us to throw our hands during her amazing Bollywood lesson, Rachna made us live in the moment and laugh, even in the hardest of times. Our hearts are with her family and friends in the days ahead and beyond.

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

Beyond devastating. Rachna was a friend to all oncologists, well known in @ASCO circles. We will all miss her. Her legacy lives on in the YIA endowed in her name.

@DrChoueiri @montypal @ERPlimackMD @aparna1024 @ErikaHamilton9

https://t.co/2Tiz2E6teK

[Madison Conces, MD @MadisonConces]

Unbelievable loss. 💔
Thinking of her family.

[Smitha Krishnamurthi @smitha42]

Rest in peace dear Rachna. 💔 https://t.co/eshYqQCExS